Related references
Note: Only part of the references are listed.Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes
Nick S. R. Lan et al.
INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING (2021)
Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study
Matthias Rau et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
David Bode et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
William T. Abraham et al.
EUROPEAN HEART JOURNAL (2021)
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Milton Packer et al.
EUROPEAN HEART JOURNAL (2021)
Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes
Sharmaine Thirunavukarasu et al.
DIABETES (2021)
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction A Substudy of the Empire HF Randomized Clinical Trial
Massar Omar et al.
JAMA CARDIOLOGY (2021)
Randomized, Controlled Trial to Evaluate the Effect of Dapagliflozin on Left Ventricular Diastolic Function in Patients With Type 2 Diabetes Mellitus The IDDIA Trial
Chi Young Shim et al.
CIRCULATION (2021)
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure
Biykem Bozkurt et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
Global longitudinal strain in heart failure with reduced ejection fraction: Prognostic relevance across disease severity as assessed by automated cluster analysis
Erberto Carluccio et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2021)
Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study
Satoshi Oka et al.
BMC CARDIOVASCULAR DISORDERS (2021)
Effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors on left ventricular remodelling and longitudinal strain: a prospective observational study
Sergio Gamaza-Chulian et al.
BMC CARDIOVASCULAR DISORDERS (2021)
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF)
Matthew M. Y. Lee et al.
CIRCULATION (2021)
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure
Biykem Bozkurt et al.
EUROPEAN JOURNAL OF HEART FAILURE (2021)
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF
Felipe A. Martinez et al.
CIRCULATION (2020)
The SGLT2 inhibitor empagliflozin reduces mortality and prevents progression in experimental pulmonary hypertension
Biswajit Chowdhury et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
In-Chang Hwang et al.
CARDIOVASCULAR DIABETOLOGY (2020)
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial
Alexander J. M. Brown et al.
EUROPEAN HEART JOURNAL (2020)
Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Petar M. Seferovic et al.
EUROPEAN JOURNAL OF HEART FAILURE (2020)
Heart Failure With Recovered Left Ventricular Ejection Fraction JACC Scientific Expert Panel
Jane E. Wilcox et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Dapagliflozin Influences Ventricular Hemodynamics and Exercise-Induced Pulmonary Hypertension in Type 2 Diabetes Patients - A Randomized Controlled Trial -
Hiroyuki Kayano et al.
CIRCULATION JOURNAL (2020)
Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium
Donato Cappetta et al.
PHARMACOLOGICAL RESEARCH (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study
Neale D. Cohen et al.
INTERNAL MEDICINE JOURNAL (2019)
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Akira Sezai et al.
CARDIOVASCULAR DIABETOLOGY (2019)
Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients
Munemitsu Otagaki et al.
CARDIOVASCULAR DRUGS AND THERAPY (2019)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction The DEFINE-HF Trial
Michael E. Nassif et al.
CIRCULATION (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus
Jung-Chi Hsu et al.
SCIENTIFIC REPORTS (2019)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
Prognostic role of left ventricular ejection fraction in heart failure: Back to the future?
Giuseppe Ambrosio et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure
Fumitaka Soga et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
Shusuke Yagi et al.
DIABETOLOGY & METABOLIC SYNDROME (2017)
Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
Nadjib Hammoudi et al.
CARDIOVASCULAR DRUGS AND THERAPY (2017)
The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Cardiomyopathy in a Diabetic Lipodystrophic Mouse Model
Michael Joubert et al.
DIABETES (2017)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Sherif F. Nagueh et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2016)
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of, Cardiovascular Imaging (vol 16, pg 233, 2015)
Lang
EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING (2016)
Definitions for a Common Standard for 2D Speckle Tracking Echocardiography: Consensus Document of the EACVI/ASE/Industry Task Force to Standardize Deformation Imaging
Jens-Uwe Voigt et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2015)
Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging
Roberto M. Lang et al.
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY (2015)
Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events Trial
Journal of the American Heart Association (2015)
Novel Predictors of Left Ventricular Reverse Remodeling in Individuals With Recent-Onset Dilated Cardiomyopathy
Milos Kubanek et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Left Ventricular Structural Remodeling in Health and Disease With Special Emphasis on Volume, Mass, and Geometry
William H. Gaasch et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Prevalence and Prognostic Significance of Left Ventricular Reverse Remodeling in Dilated Cardiomyopathy Receiving Tailored Medical Treatment
Marco Merlo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2011)
Left Ventricular Remodeling in Heart Failure Current Concepts in Clinical Significance and Assessment
Marvin A. Konstam et al.
JACC-CARDIOVASCULAR IMAGING (2011)
Presence of Extensive LV Remodeling Limits the Benefits of CRT in Patients With Intraventricular Dyssynchrony
Erberto Carluccio et al.
JACC-CARDIOVASCULAR IMAGING (2011)
Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample - The framingham heart study
Guido A. Rosito et al.
CIRCULATION (2008)
The Relationship of Left Ventricular Mass and Geometry to Incident Cardiovascular Events
David A. Bluemke et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril
J Mathew et al.
CIRCULATION (2001)